BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 16705315)

  • 1. A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.
    Newton R; Carpenter L; Casabonne D; Beral V; Babiker A; Darbyshire J; Weller I; Weiss R; Kwan A; Bourboulia D; Munoz F; Lagos D; Boshoff C
    Br J Cancer; 2006 May; 94(10):1504-9. PubMed ID: 16705315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
    Callahan J; Pai S; Cotter M; Robertson ES
    Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.
    de Souza VA; Pierrotti LC; Sumita LM; Freire WS; Segurado AA; Pannuti CS
    J Med Virol; 2007 Oct; 79(10):1562-8. PubMed ID: 17705173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray.
    Zheng D; Wan J; Cho YG; Wang L; Chiou CJ; Pai S; Woodard C; Zhu J; Liao G; Martinez-Maza O; Qian J; Zhu H; Hayward GS; Ambinder RF; Hayward SD
    J Infect Dis; 2011 Dec; 204(11):1683-91. PubMed ID: 21990424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study.
    Wakeham K; Johnston WT; Nalwoga A; Webb EL; Mayanja BN; Miley W; Elliott AM; Whitby D; Newton R
    Int J Cancer; 2015 Jun; 136(12):2822-30. PubMed ID: 25395177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutual detection of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in blood and saliva of Cameroonians with and without Kaposi's sarcoma.
    Labo N; Marshall V; Miley W; Davis E; McCann B; Stolka KB; Ndom P; Hemingway-Foday JJ; Abassora M; Newton R; Smith JS; Whitby D
    Int J Cancer; 2019 Nov; 145(9):2468-2477. PubMed ID: 31265124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.
    Gao SJ; Kingsley L; Hoover DR; Spira TJ; Rinaldo CR; Saah A; Phair J; Detels R; Parry P; Chang Y; Moore PS
    N Engl J Med; 1996 Jul; 335(4):233-41. PubMed ID: 8657239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma.
    Engels EA; Biggar RJ; Marshall VA; Walters MA; Gamache CJ; Whitby D; Goedert JJ
    AIDS; 2003 Aug; 17(12):1847-51. PubMed ID: 12891072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
    Renwick N; Halaby T; Weverling GJ; Dukers NH; Simpson GR; Coutinho RA; Lange JM; Schulz TF; Goudsmit J
    AIDS; 1998 Dec; 12(18):2481-8. PubMed ID: 9875587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells.
    Zhu L; Wang R; Sweat A; Goldstein E; Horvat R; Chandran B
    Virology; 1999 Apr; 256(2):381-92. PubMed ID: 10191203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda.
    Ziegler J; Newton R; Bourboulia D; Casabonne D; Beral V; Mbidde E; Carpenter L; Reeves G; Parkin DM; Wabinga H; Mbulaiteye S; Jaffe H; Weiss R; Boshoff C;
    Int J Cancer; 2003 Jan; 103(2):233-40. PubMed ID: 12455038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kaposi's sarcoma-associated herpesvirus seroprevalence in selected german patients: evaluation by different test systems.
    Preiser W; Szép NI; Lang D; Doerr HW; Rabenau HF
    Med Microbiol Immunol; 2001 Dec; 190(3):121-7. PubMed ID: 11827200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon.
    Stolka K; Ndom P; Hemingway-Foday J; Iriondo-Perez J; Miley W; Labo N; Stella J; Abassora M; Woelk G; Ryder R; Whitby D; Smith JS
    Cancer Epidemiol; 2014 Apr; 38(2):137-43. PubMed ID: 24631417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy.
    Guadalupe M; Pollock BH; Westbrook S; Redding S; Bullock D; Anstead G; Agan BK; Marconi VC; Barbieri S; Sankar V; Rebeles J; Flahive Y; Schoolfield J; Wang L; Lei X; Dow D; Yeh CK; Dang H; Infante AJ; Gao SJ
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):83-90. PubMed ID: 21084997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection.
    Miller G; Rigsby MO; Heston L; Grogan E; Sun R; Metroka C; Levy JA; Gao SJ; Chang Y; Moore P
    N Engl J Med; 1996 May; 334(20):1292-7. PubMed ID: 8609946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of Kaposi's Sarcoma-Associated Herpesvirus Latency Using CRISPR-Cas9 To Edit the Latency-Associated Nuclear Antigen Gene.
    Tso FY; West JT; Wood C
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda.
    Newton R; Ziegler J; Bourboulia D; Casabonne D; Beral V; Mbidde E; Carpenter L; Parkin DM; Wabinga H; Mbulaiteye S; Jaffe H; Weiss R; Boshoff C
    Br J Cancer; 2003 Aug; 89(3):502-4. PubMed ID: 12888820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy.
    Labo N; Miley W; Benson CA; Campbell TB; Whitby D
    AIDS; 2015 Jun; 29(10):1217-25. PubMed ID: 26035321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) in Kaposi's sarcoma, malignant lymphoma, and other diseases.
    Knowles DM; Cesarman E
    Ann Oncol; 1997; 8 Suppl 2():123-9. PubMed ID: 9209655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.